Q1e: 7% organic sales growth y-o-y, 10% adj. EBITA margin Expect a stronger H2, partly on lighter co...
Redeye takes a positive stance towards Avensia’s ambitious yet reasonable financial targets.
Redeye comments on the phase I biodistribution study with laquinimod eye drops and why it is importa...
Ökat fotfäste i marknaden Nettoomsättningen i kvartalet visade att bolaget ökade fotfästet i marknad...
Late yesterday evening, STRAX annanouced it intentions to divest the brands Clckr, Jewel and Fundame...
Redeye comments on events in the fourth quarter report, including progress with bacterial vaccine pr...
Redeye comments on the news that Annexin has announced a rights issue of up to SEK45m.
Hansa’s preliminary Q1 result suggests that Idefirix records European product sales of SEK 48 (43m i...
Rapportkommentar Q2 Diamyds rapport för det andra kvartalet innehöll inga överraskningar.
- Confirms a long-term obesity and diabetes device contract - No material impact next 2Y, ~SEK 700m ...
Redeye updates its estimates for the Q1 2024 report (due 2024-04-25).
Redeye is favorable to the communicated new order by Waystream just after the market closed on Thurs...
Redeye slightly increases its forecasts for Q1, 2024, and 2025 – mostly due to an expected improveme...
Redeye comments on Ngenic’s intention to divest its subsidiary Ngenic Sweden AB to Nordic Propeye fo...
Redeye takes a positive view of CombinedX’s most recent acquisition Why.
Redeye comments on Thunderful Group’s divestment of Headup.
Redeye comments on Embracer’s announced divestment of Gearbox which is acquired by Take-Two for a co...
Minor estimate revisions Expect primarily volume-driven growth FVR of SEK 20-35 reiterated What to ...
Redeye provides a short comment on Scandinavian ChemoTech's EUR48k order from a Belgian equine (hors...
Redeye trims its forecasts for Q1 2024 slightly while retaining its Base Case and comments on the FT...
